What this trial studies
Post-menopausal women who request to begin hormone-replacement therapy (HRT) are directed to the research team. The participants are tested before beginning HRT, after two months of HRT, and five months of HRT. Tests include strength performance, central nervous system functioning, body composition, resting metabolic rate, and vascular screening. The participants are provided a 12-week training intervention (2 x strength, 2 x endurance per week) that can be voluntarily followed between tests at month 2 and 5.
Conditions in scope
- Menopause
- Hormone Replacement Therapy
Interventions
- Physical training (Behavioral) — A 12-week, 4 x per week (2 x strength and 2 x endurance) training program to be performed voluntarily by the participants after tests at month 2.
Who can join
Women only · Ages 50 Years to 59 Years
Inclusion criteria
- at least 6 months since their last period but no more than being 5 years post-menopausal
- basal follicular-stimulating hormone concentration \> 30 IU/L (confirmed post-recruitment)
- willing to start combined hormonal treatment
- womb and ovaries intact with normal functioning throughout reproductive age
- willing to provide informed consent
Exclusion criteria
- classified as excessively obese via BMI assessment (i.e., \>35 kg/m2)
- intra-uterine device usage during transition to menopause
- cardiovascular or skeletomuscular disease preventing strenuous physical activity
- smoker
- diagnosed psychiatric illness
- epilepsy
- other diagnosed injuries/illness affecting the neuromuscular system
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Jyväskylä | University of Jyväskylä | Recruiting |
Status & timeline
- Overall status: Recruiting
- Study type: Interventional
- Phase: N/A
- Start date: 2026-04-25
- Primary completion: 2027-12-31
- Last update posted: 2026-05-01
- First posted: 2026-03-30
Sponsor & contact
Lead sponsor: University of Jyvaskyla (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Short-interval intracortical inhibition (SICI) (Change from baseline to month 2 and change from baseline to month 5)
Ten double-pulse transcranial magnetic stimulations delivered with 3 ms inter-stimulus interval. The conditioning pulse delivered at 80% of active motor threshold and the test pulse delivered at 120% of active motor threshold. Motor-evoked potential amplitude compared to single-pulse responses at 120% of active motor threshold.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07500922 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.